Targeted ultrasound therapy offers a less invasive prostate cancer treatment designed to minimize disruption to daily life.

Vanquish uses ultrasound, transurethral and electromagnetically guided thermotherapy to ablate prostate tissue.

Profound Medical Corp. (NASDAQ:PROF) Q4 2025 Earnings Call Transcript March 6, 2026 Operator: Good day, and thank you for ...

MINNEAPOLIS, March 5, 2026 /PRNewswire/ — Francis Medical, Inc., a privately held medical device company, announced today the successful completion of the first commercial (non-clinical trial) ...

DeepHealth, a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today unveils at ECR 2026 the industry's most comprehensive portfolio of ...

Recognising these subtle body changes can lead to an earlier diagnosis, when treatment is more likely to be successful ...

Incidental detection has increased with ubiquitous CT/MRI, inflating early-stage ‘small renal mass’ diagnoses and complicating interpretation of a ~5% rise in <50-year incidence. Obesity, hypertension ...

EDAP to Announce Fourth Quarter and Full Year 2025 Financial Results on March 25, 2026Company to host conference call and webcast on Wednesday, ...

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, ...

My daughter, the second her eyes open, without a care for anyone sleeping or what time it might be, right when the rosy ...

The company's platform integrates genomic sequencing, clinical data analytics, and AI-driven insights across oncology, cardiology, and neuropsychiatry. Tempus serves more than 50% of U.S. oncologists ...